Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    ...
    18
    ...
ATC Name B/G Ingredients Dosage Form Price
V01AA STALORAL B Allergen extracts - 10-300 IR ou IC/ml 10-300 IR ou IC/ml Solution 7,206,963 L.L
A11DB NEUROBION B Vitamin B12 - 200mcg, Vitamin B6 - 200mg, Vitamin B1 - 100mg Tablet, coated 364,181 L.L
G01AX ENTEROGERMINA B Bacillus clausii spores - 2 Billions Capsule 831,839 L.L
J02AC04 NOXAFIL B Posaconazole - 100mg 100mg Tablet, gastroresistant 62,027,714 L.L
L04AX04 REVLIMID B Lenalidomide - 25mg 25mg Capsule 127,865,045 L.L
V01AA DIATER B Allergen extracts - Spray 26,856,672 L.L
A11DB NEUROBION B Vitamin B12 - 200mcg, Vitamin B6 - 200mg, Vitamin B1 - 100mg Tablet, coated 550,975 L.L
C07AB07 CONCOR COR B Bisoprolol fumarate - 2.5mg 2.5mg Tablet, film coated 470,283 L.L
C10BX06 TRINOMIA B Acetylsalicylic acid - 100mg, Atorvastatin - 20mg, Ramipril - 2.5mg Capsule, hard 1,029,383 L.L
G01AX ENTEROGERMINA B Bacillus clausii spores - 6 Billions/2g 6 billions/2g Powder for suspension 1,493,009 L.L
J02AC05 CRESEMBA B Isavuconazonium sulfate - 100mg 100mg Capsule, hard 69,290,804 L.L
N03AG04 SABRIL B Vigabatrin - 500mg 500mg Tablet, film coated 2,988,706 L.L
V01AA DIATER B Allergen extracts - Spray 34,962,083 L.L
C10BX06 TRINOMIA B Acetylsalicylic acid - 100mg, Atorvastatin - 20mg, Ramipril - 5mg Capsule, hard 1,236,335 L.L
G01AX ENTEROGERMINA B Bacillus clausii spores - 6 Billions/2g 6 billions/2g Powder for suspension 1,343,843 L.L
H02AB04 SOLU MEDROL B Methylprednisolone sodium succinate - 500mg 500mg Injectable powder for solution 718,956 L.L
J02AC05 CRESEMBA B Isavuconazonium sulfate - 200mg 200mg Injectable powder for concentrate for solution 38,436,952 L.L
L01XA03 ELOXATIN B Oxaliplatin - 50mg/10ml 50mg/10ml Injectable concentrated solution 4,930,558 L.L
M05BA04 BINOSTO B Alendronate sodium - 70mg 70mg Tablet, effervescent 1,709,368 L.L
V01AA DIATER B Allergen extracts - Spray 35,697,531 L.L
C09DA06 ATACAND PLUS B Candesartan cilexetil - 16mg, Hydrochlorothiazide - 12.5mg Tablet 705,517 L.L
C10BX06 TRINOMIA B Acetylsalicylic acid - 100mg, Atorvastatin - 20mg, Ramipril - 10mg Capsule, hard 1,596,485 L.L
J02AX04 CANCIDAS B Caspofungin (acetate) - 70mg 70mg Injectable concentrated powder for solution 31,611,335 L.L
M05BA06 BONVIVA B Ibandronic acid - 150mg 150mg Tablet, film coated 1,265,900 L.L
N07XX02 RILUTEK B Riluzole - 50mg 50mg Tablet, film coated 15,886,212 L.L
R05D 123 COLD AND FLU B Phenylephrine HCl - 5mg, Carbinoxamine HCl - 3mg, Caffeine anhydrous - 30mg, Codeine phosphate - 8mg, Acetaminophen - 325mg Tablet 409,552 L.L
V01AA DIATER B Allergen extracts - Spray 26,856,672 L.L
C09DA06 BLOPRESS PLUS 16MG B Candesartan cilexetil - 16mg, Hydrochlorothiazide - 12.5mg Tablet 1,257,837 L.L
D01AC01 CANESTEN B Clotrimazole - 0.01g/ml 0.01g/ml Solution 368,213 L.L
G02AD02 PROPESS B Dinoprostone - 10mg 10mg Vaginal delivery system 5,838,996 L.L
    ...
    18
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025